MCID: NRG002
MIFTS: 55

Neurogenic Bladder

Categories: Nephrological diseases, Neuronal diseases

Aliases & Classifications for Neurogenic Bladder

MalaCards integrated aliases for Neurogenic Bladder:

Name: Neurogenic Bladder 12 29 6 15
Neurogenic Dysfunction of the Urinary Bladder 12
Neurogenic Urinary Bladder Disorder 12
Urinary Bladder, Neurogenic 43
Neurogenic Urinary Bladder 71
Neuropathic Bladder 12
Bladder Neurogenic 54

Classifications:



External Ids:

Disease Ontology 12 DOID:12143
ICD9CM 34 596.54
MeSH 43 D001750
NCIt 49 C79696
SNOMED-CT 67 397732007
UMLS 71 C0005697

Summaries for Neurogenic Bladder

MalaCards based summary : Neurogenic Bladder, also known as neurogenic dysfunction of the urinary bladder, is related to lethal congenital contracture syndrome 2 and vesicoureteral reflux 1, and has symptoms including seizures, vertigo and dysuria. An important gene associated with Neurogenic Bladder is EBF3 (EBF Transcription Factor 3), and among its related pathways/superpathways are CREB Pathway and Calcium signaling pathway. The drugs Acetylcholine and Silodosin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, testes and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Neurogenic bladder dysfunction, or neurogenic bladder, refers to urinary bladder problems due to disease... more...

Related Diseases for Neurogenic Bladder

Diseases related to Neurogenic Bladder via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 354, show less)
# Related Disease Score Top Affiliating Genes
1 lethal congenital contracture syndrome 2 32.3 PIP5K1C ERBB3
2 vesicoureteral reflux 1 31.3 UPK3A HPSE2 EBF3
3 low compliance bladder 31.0 P2RX3 NGF CHRM2
4 detrusor sphincter dyssynergia 30.5 TRPV1 P2RX3 P2RX2 NGF
5 bladder neck obstruction 30.4 KLK3 BCL2L10
6 pyuria 30.1 UPK3A KLK3
7 urethral stricture 30.0 KLK3 BCL2L10
8 bladder calculus 29.9 KLK3 BCL2L10
9 glandular cystitis 29.9 UPK3A KLK3
10 radiation cystitis 29.7 UPK3A P2RX1 KLK3
11 cystitis 29.6 UPK3A TRPV1 TACR1 P2RX3 NGF
12 pain agnosia 29.4 TRPV1 TACR1 NGF
13 chronic cystitis 29.3 UPK3A TRPV1 P2RX3 NGF
14 interstitial cystitis 29.2 UPK3A TRPV1 TACR1 P2RX3 NGF
15 hinman syndrome 11.9
16 urofacial syndrome 1 11.9
17 sacral defect with anterior meningocele 11.6
18 polyglucosan body neuropathy, adult form 11.4
19 adult polyglucosan body disease 11.4
20 lateral meningocele syndrome 11.3
21 lethal congenital contracture syndrome 3 11.3
22 peroxisome biogenesis disorder 10b 11.3
23 leukodystrophy, progressive, early childhood-onset 11.3
24 giant axonal neuropathy 11.3
25 cog5-congenital disorder of glycosylation 11.3
26 spinal cord injury 11.0
27 acute cystitis 10.8
28 myelomeningocele 10.8
29 neural tube defects 10.8
30 hydronephrosis 10.7
31 bacteriuria 10.6
32 pyelonephritis 10.5
33 bladder disease 10.5
34 paraplegia 10.4
35 constipation 10.4
36 spasticity 10.4
37 multiple sclerosis 10.3
38 bladder cancer 10.3
39 quadriplegia 10.3
40 herpes zoster 10.3
41 prostatic hypertrophy 10.3
42 urinary tract obstruction 10.3
43 myelitis 10.3
44 lipomatosis, multiple 10.3
45 pleomorphic lipoma 10.3
46 impotence 10.3
47 kidney disease 10.3
48 neuropathy 10.3
49 end stage renal disease 10.2
50 spinal shock 10.2
51 prostatic hyperplasia, benign 10.2
52 urolithiasis 10.2
53 hydrocephalus 10.2
54 neurogenic bowel 10.2
55 cerebral palsy 10.2
56 prostatic adenoma 10.2
57 spinal cord disease 10.2
58 acute pyelonephritis 10.2
59 47,xyy 10.2
60 48,xyyy 10.2
61 urethra cancer 10.2 UPK3A KLK3
62 systemic lupus erythematosus 10.2
63 parkinson disease, late-onset 10.2
64 spina bifida occulta 10.2
65 cauda equina syndrome 10.2
66 peripheral nervous system disease 10.2
67 chronic kidney disease 10.2
68 diabetic neuropathy 10.2
69 prostatic cyst 10.1 KLK3 BCL2L10
70 metabolic acidosis 10.1
71 sexual disorder 10.1
72 arteriovenous malformation 10.1
73 severe acute respiratory syndrome 10.1
74 ureteral obstruction 10.1
75 ileus 10.1
76 congenital zika syndrome 10.1
77 spastic paraparesis 10.1
78 back pain 10.1
79 lower urinary tract calculus 10.1 KLK3 BCL2L10
80 spinal stenosis 10.1
81 multiple system atrophy 1 10.0
82 sarcoidosis 1 10.0
83 anus, imperforate 10.0
84 arachnoid cysts, intracranial 10.0
85 exstrophy of bladder 10.0
86 exanthem 10.0
87 allergic hypersensitivity disease 10.0
88 prostatitis 10.0
89 transitional cell carcinoma 10.0
90 teratoma 10.0
91 benign ependymoma 10.0
92 cellular ependymoma 10.0
93 nephrolithiasis 10.0
94 peritonitis 10.0
95 measles 10.0
96 vasculitis 10.0
97 lupus erythematosus 10.0
98 diabetes mellitus 10.0
99 encephalopathy 10.0
100 radiculopathy 10.0
101 mononeuritis of lower limb 10.0 TRPV1 NGF
102 urethral syndrome 10.0 P2RX3 NGF KLK3
103 alcohol dependence 10.0
104 myelopathy, htlv-1-associated 10.0
105 syringomyelia, noncommunicating isolated 10.0
106 down syndrome 10.0
107 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
108 branchiootic syndrome 1 10.0
109 anxiety 10.0
110 legionnaire disease 10.0
111 lipomyelomeningocele 10.0
112 microvascular complications of diabetes 3 10.0
113 microvascular complications of diabetes 4 10.0
114 microvascular complications of diabetes 6 10.0
115 microvascular complications of diabetes 7 10.0
116 leukemia, acute lymphoblastic 3 10.0
117 alkuraya-kucinskas syndrome 10.0
118 distal arthrogryposis 10.0
119 tethered spinal cord syndrome 10.0
120 microcephaly 10.0
121 hemiplegia 10.0
122 autonomic neuropathy 10.0
123 diarrhea 10.0
124 spondylosis 10.0
125 acute kidney failure 10.0
126 tropical spastic paraparesis 10.0
127 syringomyelia 10.0
128 infertility 10.0
129 acquired immunodeficiency syndrome 10.0
130 muscular atrophy 10.0
131 chickenpox 10.0
132 genital herpes 10.0
133 diabetes insipidus 10.0
134 htlv-1 associated myelopathy/tropical spastic paraparesis 10.0
135 neonatal meningitis 10.0
136 posterior urethral valves 10.0
137 transverse myelitis 10.0
138 autonomic dysfunction 10.0
139 hydromyelia 10.0
140 congenital amyoplasia 10.0
141 bladder adenocarcinoma 9.9 UPK3A KLK3
142 lesion of sciatic nerve 9.9 TRPV1 NGF
143 causalgia 9.9 TRPV1 TACR1
144 paroxysmal extreme pain disorder 9.9 TRPV1 NGF CACNA1A
145 fibromyalgia 9.9 TACR1 P2RX3 NGF
146 urethral diverticulum 9.9 UPK3A KLK3 BCL2L10
147 cough variant asthma 9.9 TRPV1 NGF
148 trigeminal nerve disease 9.8 TRPV1 P2RX3 NGF
149 trigeminal neuralgia 9.8 TRPV1 P2RX3 NGF
150 prune belly syndrome 9.8
151 achondroplasia 9.8
152 spondyloarthropathy 1 9.8
153 congenital anomalies of kidney and urinary tract 2 9.8
154 thrombophilia due to thrombin defect 9.8
155 proteasome-associated autoinflammatory syndrome 1 9.8
156 ossification of the posterior longitudinal ligament of spine 9.8
157 multiple sclerosis 4 9.8
158 vitamin b12 deficiency 9.8
159 scoliosis 9.8
160 renal tubular acidosis 9.8
161 seminoma 9.8
162 female stress incontinence 9.8
163 distal renal tubular acidosis 9.8
164 growth hormone deficiency 9.8
165 klebsiella infection 9.8
166 testicular seminoma 9.8
167 burning mouth syndrome 9.8 TRPV1 P2RX3 NGF
168 autonomic nervous system disease 9.8 TRPV1 TACR1 NGF
169 amyotrophic lateral sclerosis 1 9.8
170 anorectal anomalies 9.8
171 cardiomyopathy, familial hypertrophic, 2 9.8
172 optic atrophy with or without deafness, ophthalmoplegia, myopathy, ataxia, and neuropathy 9.8
173 noonan syndrome 1 9.8
174 oculodentodigital dysplasia 9.8
175 osteoporosis 9.8
176 teratoma, ovarian 9.8
177 pelvic organ prolapse 9.8
178 schistosoma mansoni infection, susceptibility/ 9.8
179 spastic paraplegia 3, autosomal dominant 9.8
180 spinal arachnoiditis 9.8
181 spondylolisthesis 9.8
182 spondylosis, cervical 9.8
183 syndactyly, type iii 9.8
184 chondrosarcoma 9.8
185 cryptorchidism, unilateral or bilateral 9.8
186 mitochondrial complex iv deficiency 9.8
187 gaucher disease, type i 9.8
188 immune deficiency disease 9.8
189 leprosy 3 9.8
190 myasthenia gravis 9.8
191 myeloma, multiple 9.8
192 3-methylglutaconic aciduria, type iii 9.8
193 werner syndrome 9.8
194 xeroderma pigmentosum, variant type 9.8
195 androgen insensitivity, partial 9.8
196 supranuclear palsy, progressive, 1 9.8
197 stroke, ischemic 9.8
198 yemenite deaf-blind hypopigmentation syndrome 9.8
199 urinary tract infections, recurrent 9.8
200 intervertebral disc disease 9.8
201 diabetes mellitus, permanent neonatal 1 9.8
202 body mass index quantitative trait locus 1 9.8
203 human immunodeficiency virus type 1 9.8
204 leprosy 1 9.8
205 primary lateral sclerosis, adult, 1 9.8
206 bone mineral density quantitative trait locus 8 9.8
207 microvascular complications of diabetes 5 9.8
208 bone mineral density quantitative trait locus 15 9.8
209 corpus callosum, agenesis of, with facial anomalies and cerebellar ataxia 9.8
210 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.8
211 diabetes mellitus, permanent neonatal 4 9.8
212 rocky mountain spotted fever 9.8
213 lambert-eaton myasthenic syndrome 9.8
214 foodborne botulism 9.8
215 infant botulism 9.8
216 autosomal recessive disease 9.8
217 infective endocarditis 9.8
218 lymphoma 9.8
219 apraxia 9.8
220 ileitis 9.8
221 ptosis 9.8
222 transient neonatal diabetes mellitus 9.8
223 zika fever 9.8
224 latex allergy 9.8
225 bone disease 9.8
226 intestinal pseudo-obstruction 9.8
227 polycystic kidney disease 9.8
228 benign teratoma 9.8
229 tabes dorsalis 9.8
230 endocarditis 9.8
231 leukodystrophy 9.8
232 wolfram syndrome 9.8
233 chronic pyelonephritis 9.8
234 meningocele 9.8
235 hypospadias 9.8
236 spastic quadriplegia 9.8
237 spotted fever 9.8
238 anhidrosis 9.8
239 pertussis 9.8
240 disseminated intravascular coagulation 9.8
241 neonatal diabetes mellitus 9.8
242 lyme disease 9.8
243 cortical blindness 9.8
244 inflammatory spondylopathy 9.8
245 arachnoiditis 9.8
246 male infertility 9.8
247 retroperitoneal lymphoma 9.8
248 pancytopenia 9.8
249 porphyria 9.8
250 urethritis 9.8
251 urethral intrinsic sphincter deficiency 9.8
252 eclampsia 9.8
253 polyneuropathy 9.8
254 schistosomiasis 9.8
255 alcoholic neuropathy 9.8
256 neuroleptic malignant syndrome 9.8
257 echinococcosis 9.8
258 candidiasis 9.8
259 normal pressure hydrocephalus 9.8
260 ichthyosis 9.8
261 factitious disorder 9.8
262 vascular disease 9.8
263 gaucher's disease 9.8
264 rectum cancer 9.8
265 lateral sclerosis 9.8
266 spondylolysis 9.8
267 motor neuron disease 9.8
268 hereditary spastic paraplegia 9.8
269 gastric antral vascular ectasia 9.8
270 cystic teratoma 9.8
271 phimosis 9.8
272 pyelitis 9.8
273 endometriosis 9.8
274 cystic kidney disease 9.8
275 anuria 9.8
276 adenocarcinoma 9.8
277 churg-strauss syndrome 9.8
278 astrocytoma 9.8
279 progressive muscular atrophy 9.8
280 neurilemmoma 9.8
281 signet ring cell adenocarcinoma 9.8
282 lateral medullary syndrome 9.8
283 pituitary adenoma 9.8
284 bladder urothelial carcinoma 9.8
285 systemic scleroderma 9.8
286 hyperglycemia 9.8
287 lymphocele 9.8
288 uremia 9.8
289 prostate disease 9.8
290 poliomyelitis 9.8
291 dystonia 9.8
292 spinal cord ependymoma 9.8
293 mature teratoma 9.8
294 ovarian germ cell teratoma 9.8
295 adenoma 9.8
296 spondylitis 9.8
297 anterior spinal artery syndrome 9.8
298 lumbosacral lipoma 9.8
299 diverticulitis 9.8
300 neuroblastoma 9.8
301 cataract 9.8
302 intestinal obstruction 9.8
303 paralytic ileus 9.8
304 herpes simplex 9.8
305 nervous system disease 9.8
306 subacute delirium 9.8
307 decubitus ulcer 9.8
308 crohn's disease 9.8
309 amyloidosis 9.8
310 intracranial hypertension 9.8
311 pulmonary embolism 9.8
312 encephalitis 9.8
313 stomatitis 9.8
314 mitochondrial disorders 9.8
315 polr3-related leukodystrophy 9.8
316 aids dementia complex 9.8
317 allergic angiitis 9.8
318 allergic encephalomyelitis 9.8
319 candida glabrata 9.8
320 chromosomal triplication 9.8
321 congenital varicella syndrome 9.8
322 hansen's disease 9.8
323 horseshoe kidney 9.8
324 human t-cell leukemia virus type 1 9.8
325 pseudo-turner syndrome 9.8
326 pure autonomic failure 9.8
327 sacrococcygeal teratoma 9.8
328 sirenomelia 9.8
329 tuberculous meningitis 9.8
330 wallerian degeneration 9.8
331 depression 9.8
332 anoxia 9.8
333 brain injury 9.8
334 central cord syndrome 9.8
335 cerebral atrophy 9.8
336 chronic pain 9.8
337 dysphagia 9.8
338 hypertonia 9.8
339 hypotonia 9.8
340 spinal cord infarction 9.8
341 spinocerebellar degeneration 9.8
342 syringohydromyelia 9.8
343 tremor 9.8
344 mitochondrial neurogastrointestinal encephalomyopathy 9.8
345 urachal diverticulum 9.8
346 radiation myelitis 9.8
347 central nervous system malformation 9.8
348 overgrowth syndrome 9.8
349 oculomotor apraxia 9.8
350 agnosia 9.8 TRPV1 TACR1 NGF
351 irritable bowel syndrome 9.7 TRPV1 TACR1 NGF
352 paine syndrome 9.6 TRPV1 TACR1 P2RX3 NGF
353 somatoform disorder 9.6 TRPV1 TACR1 P2RX3 NGF
354 migraine with or without aura 1 9.1 TRPV1 TACR1 P2RX3 P2RX2 NGF CHRM2

Comorbidity relations with Neurogenic Bladder via Phenotypic Disease Network (PDN): (showing 27, show less)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Bladder Neck Obstruction Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Hypertension, Essential
Hypothyroidism Multiple Sclerosis
Osteoporosis Paralytic Ileus
Paraplegia Parkinson Disease, Late-Onset
Peripheral Vascular Disease Prostatic Hypertrophy
Protein-Energy Malnutrition Schizophreniform Disorder
Swallowing Disorders Transient Cerebral Ischemia
Urethral Stricture

Graphical network of the top 20 diseases related to Neurogenic Bladder:



Diseases related to Neurogenic Bladder

Symptoms & Phenotypes for Neurogenic Bladder

UMLS symptoms related to Neurogenic Bladder:


seizures, vertigo, dysuria, pain, meningism, reflex, abnormal, urgency of micturition, neurobehavioral manifestations, neuromuscular manifestations

MGI Mouse Phenotypes related to Neurogenic Bladder:

45 (showing 6, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 ACER3 CACNA1A CHRM2 COL6A2 ERBB3 GBE1
2 homeostasis/metabolism MP:0005376 10.1 ACER3 CACNA1A CHRM2 ERBB3 GBE1 HPSE2
3 cardiovascular system MP:0005385 10.06 CHRM2 ERBB3 GBE1 KLK3 NGF P2RX1
4 integument MP:0010771 9.81 CACNA1A CHRM2 ERBB3 NGF P2RX3 PEX3
5 nervous system MP:0003631 9.73 ACER3 CACNA1A CHRM2 EBF3 ERBB3 GBE1
6 respiratory system MP:0005388 9.17 CACNA1A CHRM2 ERBB3 GBE1 P2RX2 P2RX3

Drugs & Therapeutics for Neurogenic Bladder

Drugs for Neurogenic Bladder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 108, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Silodosin Approved Phase 4 160970-54-7
3
Morphine Approved, Investigational Phase 4 57-27-2 5288826
4
Belladonna Approved, Experimental Phase 4
5
Mirabegron Approved Phase 4 223673-61-8 9865528
6
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
8
Cefixime Approved, Investigational Phase 4 79350-37-1 5362065 54362
9
Fosfomycin Approved Phase 4 23155-02-4 446987
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
12
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
13
Methenamine Approved, Vet_approved Phase 4 100-97-0 4101
14
Fidaxomicin Approved Phase 4 873857-62-6
15
Vancomycin Approved Phase 4 1404-90-6 14969 441141
16 Cholinergic Agents Phase 4
17 Cholinergic Antagonists Phase 4
18 Neurotransmitter Agents Phase 4
19 Adrenergic Agents Phase 4
20 Adrenergic alpha-1 Receptor Antagonists Phase 4
21 Botulinum Toxins Phase 4
22 Narcotics Phase 4
23 Analgesics Phase 4
24 Opiate Alkaloids Phase 4
25 Analgesics, Opioid Phase 4
26 Adrenergic beta-Agonists Phase 4
27 Adrenergic Agonists Phase 4
28 Adrenergic beta-3 Receptor Agonists Phase 4
29 Solifenacin succinate Phase 4 242478-38-2
30 penicillins Phase 4
31 Parasympatholytics Phase 4
32 Muscarinic Antagonists Phase 4
33 Antibiotics, Antitubercular Phase 4
34 Methenamine mandelate Phase 4
35 Methenamine hippurate Phase 4
36 Anti-Infective Agents Phase 4
37 Anti-Bacterial Agents Phase 4
38
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
39
Tamsulosin Approved, Investigational Phase 2, Phase 3 106133-20-4 129211
40
Fesoterodine Approved Phase 3 286930-02-7, 286930-03-8 6918558
41
Alfuzosin Approved, Investigational Phase 3 81403-80-7 2092
42
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
43
Ofloxacin Approved Phase 3 82419-36-1 4583
44
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
45 Cranberry Approved, Investigational Phase 3
46
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
47
tannic acid Approved Phase 2, Phase 3 1401-55-4
48
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
49 Octenidine Investigational Phase 2, Phase 3 71251-02-0
50 Mitogens Phase 3
51 carnitine Phase 3
52 Omega 3 Fatty Acid Phase 3
53 Tolterodine tartrate Phase 3 124937-52-6
54 Phosphodiesterase Inhibitors Phase 3
55 Antioxidants Phase 3
56 Platelet Aggregation Inhibitors Phase 3
57 Protective Agents Phase 3
58 Radiation-Protective Agents Phase 3
59 Mandelic Acids Phase 3
60 Cola Phase 3
61 Bifidobacterium Phase 3
62 Pharmaceutical Solutions Phase 3
63
Prazosin Approved Phase 1, Phase 2 19216-56-9 4893
64
Casopitant Investigational Phase 2 414910-30-8, 414910-27-3 23725089
65 abobotulinumtoxinA Phase 2
66 Botulinum Toxins, Type A Phase 2
67 incobotulinumtoxinA Phase 2
68 Gastrointestinal Agents Phase 2
69 neurokinin A Phase 2
70 Antiemetics Phase 2
71
Substance P Phase 2 33507-63-0 44359816
72
Methantheline Approved, Investigational Phase 1 5818-17-7 4097
73 Bromides Phase 1
74
Norepinephrine Approved 51-41-2 439260
75
Finasteride Approved 98319-26-7 57363
76
Dutasteride Approved, Investigational 164656-23-9 152945 6918296
77
Sulfamethoxazole Approved 723-46-6 5329
78
Trimethoprim Approved, Vet_approved 738-70-5 5578
79
leucovorin Approved 58-05-9 6006 143
80
Ciprofloxacin Approved, Investigational 85721-33-1 2764
81
Ampicillin Approved, Vet_approved 69-53-4 6249
82
Nitrofurantoin Approved, Vet_approved 67-20-9 5353830
83
Cephalexin Approved, Investigational, Vet_approved 15686-71-2 27447
84
Doxycycline Approved, Investigational, Vet_approved 564-25-0 54671203
85
Cefpodoxime Approved, Vet_approved 80210-62-4, 82619-04-3 6335986
86
Epinephrine Approved, Vet_approved 51-43-4 5816
87
Racepinephrine Approved 329-65-7 838
88
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
89
Imidacloprid Vet_approved 105827-78-9 86418
90 Anti-Infective Agents, Local
91 Hormone Antagonists
92 Hormones
93 5-alpha Reductase Inhibitors
94 Vaccines
95 Gentamicins
96 Cytochrome P-450 Enzyme Inhibitors
97 Folic Acid Antagonists
98 Vitamin B Complex
99 Antiparasitic Agents
100 Folate
101 Antiprotozoal Agents
102 Trimethoprim, Sulfamethoxazole Drug Combination
103 Vitamin B9
104 Antimalarials
105 Cefpodoxime proxetil
106 Epinephryl borate
107 Anesthetics, General
108 Fibrin Tissue Adhesive

Interventional clinical trials:

(showing 170, show less)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
2 Randomized Placebo-Controlled Trial of Gentamicin Bladder Instillation for the Prevention of Urinary Tract Infection in Adults at High Risk for Cystitis Due to Intermittent Catheterization Unknown status NCT01884467 Phase 4 Gentamicin;Placebo
3 A 12-week, Open-label, Multi-center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder Completed NCT01228370 Phase 4 silodosin
4 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository: A Randomized, Double-Blind, Placebo-Controlled Trial (ROBIN Trial) Completed NCT02600715 Phase 4 Onabotulinumtoxin A (BoNT);belladonna;Morphine;Placebo;Active B&O suppository of belladonna
5 Quality of Life Intermittent Catheter Study - A Prospective, Randomized, Cross-over, Multicenter Study Comparing Quality of Life Using Compact Versus Standard Urinary Intermittent Catheters Completed NCT01523743 Phase 4
6 A Randomized, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4 Weekly Oral Cyclic Antibiotic programme
7 A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
8 Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy Completed NCT01421719 Phase 4 Cystoscopic injection of Botox into the urinary bladder
9 A Prospective, Randomized, Parallel-group, Multi-center Study to Compare the Occurrence of Urinary Tract Infections in Patients With Spinal Cord Injury Using Either Coated or Uncoated Intermittent Catheters. Completed NCT00318591 Phase 4
10 A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury Completed NCT00224029 Phase 4 Oxybutynin transdermal system
11 Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury Completed NCT02298660 Phase 4 BOTOX
12 Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome (Cts): A Randomized, Placebo-Controlled Trial With Secondary Bayesian Modification Completed NCT00277563 Phase 4
13 The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1 Completed NCT02384200 Phase 4 nitrofurantoin monohydrate/macrocrystalline capsules;ampicillin;gentamicin;vancomycin;ceftriaxone
14 Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
15 A Two-part, Multicenter, Dose-titration Study Evaluating Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Oxybutynin Chloride 10% Gel for Treatment of Detrusor Overactivity Associated Neurological Condition in Pediatric Patients Recruiting NCT01192568 Phase 4 Oxybutynin
16 The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing Due to New Episodes of Urinary Tract Infections (UTI) in Elderly Women With Recurrent UTI - a Triple- Blinded, Randomized Placebo-controlled Phase IV Study Enrolling by invitation NCT04077580 Phase 4 Methenamine Hippurate 1000 MG
17 Role of Fidaxomicin in a Patient Population With Problematic Clostridium Difficile Infection Terminated NCT02355938 Phase 4 Fidaxomicin 200 mg;Placebo;Vancomycin
18 Antiseptic-coated Intermittent Urinary Catheter: Efficacy and Feasibility of Neurogenic Bladder Management and Prevention of Catheter-associated Urinary Tract Infections in Children Unknown status NCT02697162 Phase 2, Phase 3 Octenidine chloride
19 The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
20 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
21 A Double-Blind, Randomized Study of the Safety and Efficacy of OnabotulinumtoxinA (OnaBoNT-A) Versus Oral Oxybutynin in Spinal Cord Injured Patients With Neurogenic Detrusor Overactivity (Protocol Number 11-09-10-04) Unknown status NCT01050114 Phase 3 onaBoNT-A;Oxybutynin ER
22 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
23 A Phase IIb/III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Dose Ranging Study of Tamsulosin Hydrochloride (Low, Medium and High Dose) as Treatment in Children With Neuropathic Bladder for Three Months Completed NCT00796614 Phase 2, Phase 3 tamsulosin hydrochloride;Placebo
24 A Pilot Study Comparing the Effects of Botulinum Toxin A and Standard Oxybutynin Therapy as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder Completed NCT01716624 Phase 3 Oxybutynin;Botulinum Toxin A injection
25 A 24-WEEK RANDOMIZED, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 17 YEARS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) Completed NCT01557244 Phase 3 Fesoterodine PR 4 mg;Fesoterodine PR 8 mg;Fesoterodine PR 8 mg;Oxybutynin;Fesoterodine PR;Fesoterodine BIC 2 mg;Fesoterodine BIC 4 mg
26 LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) WHO HAVE COMPLETED 24 WEEKS TREATMENT IN STUDY A0221047 Completed NCT02501928 Phase 3 Fesoterodine PR 4 mg;Fesoterodine PR 8 mg;Fesoterodine BIC 2 mg;Fesoterodine BIC 4 mg
27 Four-week, Open-label, Multicenter, Randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety, Tolerability and the Effects on Leak Point Pressure of Two Oral Doses of Alfuzosin (0.1 mg/kg/Day; 0.2 mg/kg/Day) in Children and Adolescents 2 to 16 Years-of-age With Elevated Detrusor Leak-point Pressure of Neuropathic Etiology Completed NCT00629720 Phase 3 alfuzosin (SL770499)
28 12-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy, Pharmacodynamic and Safety of 2 Doses of Alfuzosin (0.1 mg/kg/Day, 0.2 mg/kg/Day) in the Treatment of Children and Adolescents 2-16 Years With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension Completed NCT00549939 Phase 3 Alfuzosin;Placebo
29 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) Completed NCT01600716 Phase 3 Placebo (Normal Saline)
30 12-week, Multicenter, Open-label, Non-comparative Study to Investigate Pharmacodynamic and Safety of Alfuzosin 0.2 mg/kg/Day in the Treatment of Children and Adolescents 2 - 16 Years of Age With Hydronephrosis Associated With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension Completed NCT00576823 Phase 3 Alfuzosin
31 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
32 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
33 Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients. Completed NCT00280592 Phase 3 Cranberry;Placebo
34 Oxybutynin for Post-surgical Bladder Pain and Urgency Recruiting NCT03952299 Phase 3 Oxybutynin Transdermal Patch;Oral Oxybutynin
35 Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS) Recruiting NCT03774407 Phase 2, Phase 3 vaginal estriol
36 The Effect of Gentamicin Intravesical Installations on Decreasing Urinary Tract Infections in Patients With Neurogenic Bladder After Spinal Cord Injury: A Clinical Trial Active, not recruiting NCT03503513 Phase 2, Phase 3 Gentamicin Sulfate;Saline
37 Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters Not yet recruiting NCT04323735 Phase 3 Culturelle 10 Billion CFU Capsule
38 Intravesical Lactobacillus to Reduce Urinary Symptoms After Spinal Cord Injury Not yet recruiting NCT04373512 Phase 3 Culturelle 10 Billion CFU Capsule (2 doses);Culturelle 10 Billion CFU Capsule (4 doses)
39 Use of Novel Human Milk Prebiotics to Improve the Quality of Life for Spinal Cord Injury Patients With Bowel and Bladder Dysfunction Not yet recruiting NCT03987126 Phase 3
40 A Double Blind, Randomized Placebo Controlled Trial Evaluating the Urodynamic and Clinical Efficacy of Mirabegron Among Neurogenic Bladder Patients Terminated NCT02044510 Phase 2, Phase 3 Mirabegron;Placebo
41 Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
42 Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction Unknown status NCT00602186 Phase 1, Phase 2 tamsolusin;prazosin
43 A Clinical Trial to Determine the Extent to Which Probiotic Therapy Reduces Side Effects of Antibiotic Prophylaxis in Pediatric Neurogenic Bladder Patients With a History of Recurrent Urinary Tract Infections Unknown status NCT02044965 Phase 1, Phase 2 Probiotic
44 An Uncontrolled, Open-label, Titration, Long-term Safety (up to 12 Months) and Efficacy Study of Tamsulosin Hydrochloride in Children With Neuropathic Bladder, With a Randomized Pharmacokinetic Sub-study Investigating Low, Medium and High Dose Ranges. Completed NCT00340704 Phase 2 tamsulosin hydrochloride
45 Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study Completed NCT02591901 Phase 2 Uro vaxom
46 Self-management of Urine Flow in Long-term Urinary Catheter Users Completed NCT00883220 Phase 2
47 Multifaceted Treatment of Catheter-related Urinary Tract Infection Completed NCT00732238 Phase 2
48 A Multicenter, Double-blind, Crossover Design, Pilot Study to Evaluate the Effect of NVC-422 Catheter Irrigation on Urinary Catheter Patency Completed NCT01243125 Phase 2 NVC-422, 0.2%;Sterile normal saline, 0.9%
49 Lumbar to Sacral Ventral Nerve Re-Routing Completed NCT00378664 Phase 2
50 A Treatment Trial of Triheptanoin in Patients With Adult Polyglucosan Body Disease - A Randomized Controlled Study Completed NCT00947960 Phase 2 Triheptanoin
51 UTI Prophylaxis Using Bacterial Interference Following SCI Completed NCT00037921 Phase 2
52 The Impact of Self-Management With Probiotics on Urinary Symptoms and the Urine Microbiome in Individuals With Spinal Cord Injury (SCI) and Spina Bifida (SB) Completed NCT02748356 Phase 2 Lactobacillus
53 The Impact of Self-Management With Probiotics on Urinary Symptoms and the Urine Microbiome in Individuals With Spinal Cord Injury (SCI) and Spina Bifida (SB)" Completed NCT02748317 Phase 2 Lactobacillus rhamnosus GG
54 Comparison of the Therapeutic Effects of Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome Completed NCT01657409 Phase 2 BoNT-A (10 injection);BoNT-A (20 injection);BoNT-A (40 injection)
55 Comparative Study of Safety and Efficacy Between 100 U Suburothelial Injection and 50 U Suburothelial Plus 50 U Urethral Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility Completed NCT02135341 Phase 2 Botulinum toxin A;Botulinum toxin A
56 Efficacy and Tolerability of Mirabegron Compared to Oxybutynin Chloride Immediate Release for Neurogenic Detrusor Overactivity in Persons With Chronic Spinal Cord Injury: A Randomized, Double-Blind, Controlled, Cross-Over Clinical Trial Recruiting NCT03187795 Phase 2 Oxybutynin Chloride IR;Mirabegron
57 The Evaluation of Antimicrobial Bladder Instillation on the Prevalence of Chronic Urinary Tract Infections and Bladder Dysfunction in Persons With Spinal Cord Injury Recruiting NCT03931408 Phase 2 Gentamicin Sulfate
58 A Phase I/II Study of Bacteriophage Therapy to Evaluate Safety, Tolerability, and Efficacy of Targeted "Personalized" Bacteriophage Treatments in Patients With Bacterial Infection of the Urinary Tract Not yet recruiting NCT04287478 Phase 1, Phase 2
59 An Open Label Multicenter Study of Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury Terminated NCT00512148 Phase 2
60 A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy Terminated NCT01598103 Phase 2 SAF312;Placebo to SAF312
61 An Open-Label Multicenter Study of Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct in Subjects With Spina Bifida Terminated NCT00419120 Phase 2
62 Botulinum Toxin A Treatment of Detrusor External Sphincter Dyssynergia During Early Spinal Cord Injury (Protocol #H-20344) Terminated NCT00711087 Phase 2 BOTOX-A
63 See Detailed Description Terminated NCT00332319 Phase 2 GW679769
64 Evaluation of the Efficacy and Tolerance of 2 Dosages of Type A Botulinic Toxin in Neurogenic Areactive Bladder Resistant to Oral Medical Treatment Terminated NCT00213577 Phase 2 type A botulinum toxin
65 Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization Withdrawn NCT01305681 Phase 1, Phase 2
66 Probiotics Improvement of Gastrointestinal and Genitourinary Health in Girls With Spina Bifida (H-23245) Withdrawn NCT00767988 Phase 2
67 Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach. Withdrawn NCT00262496 Phase 2 Botox
68 Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery Withdrawn NCT00770705 Phase 2 Phenoxybenzamine
69 Bacteriuria Eradication Through Probiotics Unknown status NCT00717600 Phase 1
70 Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution Completed NCT01429090 Phase 1 Vagantin®;methantheline solution
71 Colonizing Neurogenic Bladders With Benign Flora Completed NCT00371631 Phase 1
72 Evaluate the Safety in Human Subjects of Using Bladder Catheters That Are Pre-Coated With a Biofilm That Contains Living Bacteria Escherichia Coli 83972. Completed NCT00458471 Phase 1
73 Tissue Bonding Cystostomy(TBC) Not yet recruiting NCT01771159 Phase 1
74 Clinical Study Evaluating Safety of a New Catheter for Urinary Intermittent Catheter in Healthy Volunteers Withdrawn NCT01292941 Phase 1
75 The Efficacy of Botulinum Toxin in Spastic Neuropathic Bladder Unknown status NCT03407183
76 Impact of Activity-Dependent Plasticity on Bladder Function After Pediatric Spinal Cord Injury Unknown status NCT03559036
77 Urinary and Sexual Function Before and After Surgical Decompression of Cervical Myelopathy Unknown status NCT02059798
78 A Prospective Evaluation of the Catheter Science C3 "Umbrella Catheter" for Patients With Urinary Retention Due to Bladder Dysfunction (C3 Catheter Study) Unknown status NCT03353571
79 Gene Expression in the Bladder in Children With an Overactive Bladder and Daytime Urinary Incontinence Unknown status NCT02086058
80 Neurogenic Overactive Bladder Treatment on Parkinson's Disease Through Back Tibial Nerve Electrostimulation Unknown status NCT02583529 Early Phase 1
81 The Effects of Stroke Related Neurogenic Bladder on The Quality of Life: A Study of Turkish Population Completed NCT04072796
82 Comparing the Efficacy of Two Doses of Onabotulinum Toxin for the Treatment of Neurogenic Detrusor Overactivity - a Retrospective Cohort Study Completed NCT03388086 Injection of Onabotulinum toxin
83 Turkish Version of the Neurogenic Bladder Symptom Score Questionnaire: a Cross-cultural Adaptation, Reliability and Validity Study Completed NCT03964077
84 Effects of Bladder Management on Health-related Quality of Life in Patients With Neurogenic Bladder Completed NCT02179073
85 Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder Completed NCT02673047
86 Effects of Antimuscarinic Drugs on the Cognition of Patients With Acute Spinal Cord Injury Completed NCT01600404 antimuscarinic treatment
87 Can Dynamic Ultrasonography Replace Urodynamics in the Follow-up of Patients With Myelomeningocele: A Prospective Concurrent Study Completed NCT03550898
88 A Randomized Trial of Transcutaneous Nerve Stimulation for Neurogenic Bladder Completed NCT02582151
89 Sonographic Measurement of Bladder Wall Thickness in Patients With Neurogenic Bladder Dysfunction Due to Spinal Cord Injury Completed NCT01299792
90 Incidence of Urinary Tract Infection and Germ Identification After Urodynamic Investigation in Patients With Spinal Cord Injury Completed NCT01297647
91 Efficacy Of Pulsed Electromagnetic Field Therapy On Neurogenic Bladder in Children With Myelomeningocele Completed NCT04187027
92 Is the Detrusor Contraction During the Ice-water-test Provoked by the Ice Water or the Rapid Bladder Filling? A Randomized, Double-blind Clinical Trial Completed NCT01773213
93 Heart Rate Variability in Patients With Neurogenic Detrusor Overactivity Before and After Botulinum Neurotoxin Type A Intradetrusor Injections Completed NCT01337024
94 Home Neuromodulation of the Neurogenic Bladder in Chronic Spinal Cord Injury With Transcutaneous Tibial Nerve Stimulation Completed NCT03458871
95 Retrospective Study With Botulinic Toxin in Neurogenic Detrusor Overactivity Completed NCT03042052 detrusor infection of Botulinum toxin
96 The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury Completed NCT02573402
97 Use of a Diurnal Indwelling Urethral Catheter to Improve Quality of Life for Patients With Spina Bifida and Spinal Cord Injury Completed NCT03573726
98 Prospective Comparative Multicenter Study on the Medico-economical Impact of the Brindley Technique in the Management of Neurogenic Bladder in Patients With Injured Spinal Cord Completed NCT00221767
99 Investigation of Lower Urinary Tract Afferent and Cortical Brain Activity During Lower Urinary Tract Stimulation Using Electroencephalogram Measurements Completed NCT01389921
100 Clinical Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction Completed NCT03405285
101 Neuro-urological Outcome After Spinal Cord Injury Completed NCT01297660
102 Randomized Clinical Trial Using Sterile Single-use and Reused Polyvinylchloride Catheter For Intermittent Catheterization With Clean Technique In Neurogenic Bladder Due to Spina Bifida Completed NCT03424499
103 A Prospective Study of Higher Neural Control Changes Following Intradetrusor Injection of BotulinumtoxinA in Patients With Multiple Sclerosis and Lower Urinary Tract Symptoms. Completed NCT03033355 Intradetrusor injection of Botulinum Toxin-A
104 Applying Health Mechanics to Enhance Bowel and Bladder Health for Persons With SCI Completed NCT01920243
105 A Biochip for Rapid Diagnosis of Complicated Urinary Tract Infection Completed NCT00591240
106 Clinical Evaluation of Connected Catheter 2P (C2P) Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction Completed NCT03626324
107 A Comparison of the Incidence of Symptomatic Urinary Tract Infections in Children With Spina Bifida Using Hydrophilic or Non-hydrophilic Polyvinyl Chloride Catheters for Clean Intermittent Catheterization: a Randomized Cross Over Trial Completed NCT01263392
108 Effect of Botulinum Toxin A on Neurogenic Detrusor Overactivity in Chronic Spinal Cord Injured Patients - An Investigation of Sensory Receptor Expressionsbetween Responders and Non-responders Completed NCT03063827 OnabotulinumtoxinA 200 UNT
109 Vesico-ureteral Reflux in a Contemporary Series of Spinal Cord Injury Patients With Neurogenic Lower Urinary Tract Dysfunction Completed NCT01297673
110 A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity Completed NCT01477736 Oxybutynin;Botulinum toxin A
111 Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1 Completed NCT01651819
112 Autonom Dysrefleksi Ved Rygmarvsskade Completed NCT01059370
113 Comparative Study of Two Different Urine Catheters. Completed NCT01142115
114 Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury? Completed NCT02138149
115 The Effect of Pelvic Floor Muscle Training and Neuromuscular Electrical Stimulation on Urinary Incontinence and Quality of Life in Women With Spinal Cord Injury Completed NCT02427230 vaginal electrical stimulator (CefarPeristim Pro)
116 The Course of Post-stroke Bladder Problems and Their Relation With Functional, Mental Status and Quality of Life: A Six-month Prospective, Multicenter Study Completed NCT03174600
117 A Pilot Investigation of Dutasteride (Avodart) After Failure of Finasteride (Proscar) In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H) Completed NCT00382356 Dutasteride
118 Filling and Emptying Cystometries: a Feasibility and Validation Study in Order to Simplify the Manometric Follow-up of Overactive Detrusor in Neurological Patients Under Anticholinergic or Botulinum Toxin Injections. Completed NCT03255421
119 Evaluation of Neurologic Complications Associated With Surgical Correction of Adult Spinal Deformity: A Prospective, Observational, Multi-center Study Completed NCT01305343
120 The Bladder and the Brain - Investigation of the Supraspinal Neural Control of Lower Urinary Tract Function in Healthy Subjects and Patients With Neurogenic and Non-neurogenic Bladder Dysfunction Using Advanced Neuroimaging Techniques Completed NCT01768910
121 Evaluation of Neurologic Complications Associated With Surgical Correction of Adult Spinal Deformity (Scoli-RISK-1): A Prospective, Observational, Multi-center Study 5 Year Follow-up Extension Completed NCT02949245
122 Somato-sensory Reflex Arch in Spinal Cord Injury - Effect on Colorectal Transport Completed NCT01274312
123 Somato-sensory Reflex Arch in Spinal Cord Injury - Effect on Clinical Outcome Completed NCT01241630
124 Prevention of UTI in Persons With Spinal Cord Injury Completed NCT00309114
125 Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use Recruiting NCT04128709
126 Efficacité Clinique comparée de la Stimulation transcutanée du Nerf Tibial postérieur unilatérale vs bilatérale Pour Traiter Une hyperactivité vésicale Neurologique Non sévère : Essai Clinique randomisé Recruiting NCT04225143
127 Evaluation of Noninvasive Spinal Cord Stimulation for Neurogenic and Idiopathic Overactive Bladder Recruiting NCT03753750
128 Multicenter Pilot and Exploration Study of Enhanced Recovery After Surgery (ERAS) in Patients Undergoing Urologic Reconstructive Surgery Recruiting NCT03245242
129 Clinical Evaluation of the Connected Catheter - Wireless Urinary Prosthesis for Management of Chronic Urinary Retention Recruiting NCT04059159
130 Database of Patients With Lower Urinary Tract Dysfunction Treated at the University of Zürich Recruiting NCT01293110
131 The Effectiveness of Early Sacral Nerve Stimulation in Improving Bladder- Related Complications and Quality of Life After Acute Traumatic Spinal Cord Injury Recruiting NCT03083366
132 Long Term Genital Nerve Stimulation to Improve Urinary Continence Recruiting NCT03472599
133 Impact of Percutaneous Posterior Tibial Nerve Stimulation on Urinary and Global Quality of Life in Multiple Sclerosis Patients Recruiting NCT04063852
134 Supraspinal Mechanisms Involved in Voiding Dysfunction. Recruiting NCT03574610
135 Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction Reveal Common Signalling Pathways Relevant for Disease Progression and Recovery Recruiting NCT02410876
136 Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicenter, Randomised, Sham-controlled, Double-blind Clinical Trial Recruiting NCT04315142
137 The Impact of Deep Brain Stimulation in Patients With Lower Urinary Tract Symptoms: A Prospective, Observational, Cohort Study Recruiting NCT03202251
138 Urodynamic Evaluation Neurgenic Bladder in Patients After Spinal Cord Injury Recruiting NCT04231474
139 Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation Recruiting NCT04074616
140 Clinical Evaluation of the Connected Catheter- Wireless Urinary Prosthesis for Management of Chronic Urinary Retention Recruiting NCT03843073
141 Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy Recruiting NCT03593512
142 Restoration of Bladder and Bowel Function Using Electrical Stimulation and Block After Spinal Cord Injury Recruiting NCT02978638
143 Long Term Assessment and Outcome of Adult Patients With Congenital Genitourinary Abnormalities. Recruiting NCT03061084
144 Polish Translation and Validation of the Neurogenic Bladder Symptom Score (NBSS), Qualiveen and Short Form Qualiveen (SF-Qualiveen) Questionnaires Recruiting NCT04185792
145 The Impact of Electroacupuncture on Clinical Effect,Brain Structural and Functional Changes in Patients With Spinal Cord Injury:A Randomized Controlled Study Based on Multi-mode MRI Recruiting NCT03909958
146 A Randomized, Prospective, Single-Blinded Control Trial to Assess the Need for Antibiotic Prophylaxis With Routine Ureteral Stent Removal After Kidney Stone Procedure Recruiting NCT02944825 Ciprofloxacin;trimethoprim/sulfamethoxazole;No Intervention
147 Prospective, Controlled, Randomized Multicentric Study of Non-inferiority on the Management of the Vesical Catheter in Colon Surgery. CR-Vesical Cath Study Group Recruiting NCT04070898
148 The Endourology Disease Group for Excellence (EDGE) Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy in Patients With Moderate Risk of Postoperative Infection Recruiting NCT02829060 Nitrofurantoin 100 MG, 7d;Gentamicin, 5mg/kg;Ampicillin 2g;Nitrofurantoin 100 mg, 48 hrs;Gentamicin, 80 mg, 7d;Gentamicin, 80 mg, 48hr
149 Wolfram Syndrome International Registry and Clinical Study Recruiting NCT02841553
150 Patient Reported Outcomes for Bladder Management Strategies in Spinal Cord Injury Active, not recruiting NCT02616081
151 Transcutaneous Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction Active, not recruiting NCT02859844
152 Feasibility of Detecting Functional Changes in the Brain After Tibial Nerve Stimulation and the Association With the Sacral Roots Architecture: a Pilot Magnetic Resonance Study Active, not recruiting NCT03908047
153 Evaluation of the German Short-Form Qualiveen Questionnaire Active, not recruiting NCT03898258
154 Non-invasive Nerve Stimulation for Inhibition of Bladder Incontinence in Spinal Cord Injured Subjects. Active, not recruiting NCT03877432
155 Mid Term Safety and Efficacy of ALTIS® Single Incision Sling for Female SUI. Less Mesh, Same Results. Active, not recruiting NCT03620604
156 Measurement of Bladder Pressure With a Novel External Device, Comparison to Urodynamics Testing Enrolling by invitation NCT03456089
157 Low Energy Surface Waves to Prevent Urinary Infections and Catheter Associated Symptoms Among Patients With Neurogenic Bladder Dysfunction Enrolling by invitation NCT03785262
158 Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: an Open Label Pilot Study of Anticholinergic Agent vs. Mirabegron (MYRBETRIQ ®) to Evaluate Cognitive Impact and Efficacy Enrolling by invitation NCT03612401 Early Phase 1 Mirabegron
159 Prospective Randomized Controlled Trial Comparing the Non-invasive vs the Invasive Investigations in Multiple Sclerosis Patients With Urinary Disorders. Enrolling by invitation NCT03336424
160 Clinical Outcomes of Laser Prostatectomy Enrolling by invitation NCT03318991
161 Qualitative Assessment of the Impact of the Connected Catheter on Quality of Life and Participation Not yet recruiting NCT04248322
162 EVALUATION OF THE SAFETY AND EFFICACY OF ADJUSTABLE CONTINENT THERAPY FOR THE MANAGEMENT OF NEUROGENIC INCONTINENCE IN CHILDREN WITH SPINAL DYSRAPHISM. Not yet recruiting NCT03351634
163 Feasibility of Using CeVUS During Urodynamic Studies Not yet recruiting NCT04170413 CeVUS
164 Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder Not yet recruiting NCT04350359
165 Effects of Activity-Dependent Plasticity on Recovery of Bladder and Sexual Function After Human Spinal Cord Injury Not yet recruiting NCT04193709
166 Measurement of Bladder Function Change In Patients With Spinal Vascular Malformations Before and After Surgical Intervention Not yet recruiting NCT03280186
167 Urothelium Tissue Engineering Using Bladder Mucosa From Transurethral Resection of Prostate Not yet recruiting NCT03698721
168 Case Control Study to Investigate the Use of Urethral Pressure Profile Measurement in Children Not yet recruiting NCT04147793
169 A Prospective Trial of Division of the Filum Terminale for Neurogenic Bladder Dysfunction With a Normal Conus Terminated NCT01465581
170 Safety and Efficacy of Nerve Rerouting for Treating Neurogenic Bladder in Spina Bifida Withdrawn NCT01096459

Search NIH Clinical Center for Neurogenic Bladder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Baclofen
Bethanechol
Bethanechol Chloride
Hyoscyamine
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
oxybutynin
Oxybutynin chloride

Cochrane evidence based reviews: urinary bladder, neurogenic

Genetic Tests for Neurogenic Bladder

Genetic tests related to Neurogenic Bladder:

# Genetic test Affiliating Genes
1 Neurogenic Bladder 29

Anatomical Context for Neurogenic Bladder

MalaCards organs/tissues related to Neurogenic Bladder:

40
Spinal Cord, Testes, Brain, Kidney, Prostate, Colon, Heart

Publications for Neurogenic Bladder

Articles related to Neurogenic Bladder:

(showing 4082, show less)
# Title Authors PMID Year
1
Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. 61 54
12783571 2003
2
Caudal regression syndrome (Currarino syndrome) with chromosom mutation 9. 61
32550955 2020
3
Malignancy after Augmentation Enterocystoplasty: A Nationwide Study of Natural History, Prognosis and Oncogene Panel Analysis. 61
31957550 2020
4
Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review). 61
32509003 2020
5
Overactive bladder and urgency urinary incontinence in men undergoing artificial urinary sphincter placement. 61
32339308 2020
6
Iatrogenic bladder rupture in individuals with disability related to spinal cord injury and chronic indwelling urethral catheters. 61
32513945 2020
7
Neurological Complications and Associated Risk Factors in Children Affected with Chronic Kidney Disease. 61
32521637 2020
8
Has the use of preoperative urodynamics for stress urinary incontinence surgery changed following the VALUE study? 61
32559352 2020
9
Case Report: Recurrent Pyometra in an Adolescent. 61
32574600 2020
10
Urodynamic findings during the filling phase in neurogenic bladder patients with or without vesicoureteral reflux who have undergone sacral neuromodulation. 61
32282088 2020
11
URINARY TRACT ANOMALIES IN PATIENTS WITH ANORECTAL MALFORMATIONS: THE ROLE OF SCREENING AND CLINICAL FOLLOW-UP. 61
32525076 2020
12
Intravesical hyaluronic acid treatment in recurrent urinary tract infections in children with spina bifida and neurogenic bladder. 61
32197933 2020
13
Complications in adulthood for patients with paediatric genitourinary reconstruction. 61
32529452 2020
14
Vesicocutaneous fistula: continent vesicostomy, an easier route for comfortable clean intermittent catheterization. 61
32171665 2020
15
Cauda equina syndrome: false-positive diagnosis of neurogenic bladder can be reduced by multichannel urodynamic study. 61
31907657 2020
16
Development and validation of a bladder trabeculation grading system in pediatric neurogenic bladder. 61
32247670 2020
17
Re: Reasons for Cessation of Clean Intermittent Catheterization after Spinal Cord Injury: Results from the Neurogenic Bladder Research Group Spinal Cord Injury Registry. 61
32567969 2020
18
Neurogenic bladder symptom score: Polish translation, adaptation and validation of urinary disorder-specific instrument for patients with neurogenic lower urinary tract dysfunction. 61
32515531 2020
19
Contemporary multicenter outcomes of continent cutaneous ileocecocystoplasty in the adult population over a 10-year period: A Neurogenic Bladder Research Group study. 61
32506711 2020
20
Use of oral third generation cephalosporins and quinolones and occurrence of antibiotic-resistant strains in the neurogenic bladder (NB) outpatient setting: a retrospective chart audit. 61
31965059 2020
21
Anterior Urethral Valve - A Commonly Misdiagnosed Entity in Adolescent Boys. 61
32087211 2020
22
Diet in neurogenic bowel management: A viewpoint on spinal cord injury. 61
32523306 2020
23
Stepwise Description and Outcomes of Bladder Neck Sparing Robot-Assisted Simple Prostatectomy. 61
32183554 2020
24
The correlation between diffusion tensor imaging of the sacral cord and bladder contractility in people with tetraplegia. 61
32415223 2020
25
Change in urodynamic pattern and incidence of urinary tract infection in patients with traumatic spinal cord injury practicing clean self-intermittent catheterization. 61
30277852 2020
26
The intravesical injection of highly purified botulinum toxin for the treatment of neurogenic detrusor overactivity. 61
32432536 2020
27
Development and Validation of Symptom Score for Total Bladder-Bowel Dysfunction; Subscales for Overactive Bladder and Dysfunctional Voiding. 61
32469626 2020
28
In Silico Subtractive Proteomics Approach for Identification of Potential Drug Targets in Staphylococcus saprophyticus. 61
32455889 2020
29
Stem Cell Therapy for Neurogenic Bladder After Spinal Cord Injury: Clinically Possible? 61
32482052 2020
30
[Course of neurogenic bladder dysfunction in patients with spinal cord injury under homeopathic treatment]. 61
32424576 2020
31
Indwelling catheterization, renal stones, and hydronephrosis are risk factors for symptomatic Staphylococcus aureus-related urinary tract infection. 61
32363449 2020
32
Dialysis in Pregnancy: Role of the Underlying Cause of Renal Failure on Peripartum Outcomes. 61
31910463 2020
33
The incidence and effect of tethered cord release for tethered cord syndrome in patients with myelomeningocele: a population-based study. 61
32470933 2020
34
Frequency of patient-reported UTIs is associated with poor quality of life after spinal cord injury: a prospective observational study. 61
32409777 2020
35
Urological Evaluation of Tethered Cord Syndrome. 61
32392667 2020
36
Re: Reasons for Cessation of Clean Intermittent Catheterization after Spinal Cord Injury: Results from the Neurogenic Bladder Research Group Spinal Cord Injury Registry. 61
32421407 2020
37
Re: A Cross-Sectional Study of the Catheter Management of Neurogenic Bladder after Traumatic Spinal Cord Injury. 61
32396432 2020
38
Urinary Symptoms and Bladder Dysfunction in Patients with Neuromyelitis Optica Spectrum Disorders: Evaluation with Urodynamics and Management. 61
32367978 2020
39
Short-term outcomes of laparoscopic lateral pelvic node dissection for advanced lower rectal cancer. 61
32246236 2020
40
The Stockholm Spinal Cord Uro Study: 2. Urinary tract infections in a regional prevalence group: frequency, symptoms and treatment strategies. 61
32148149 2020
41
Use of a Closed Diurnal Indwelling Catheter for Patients With Spinal Cord Disorders: A Pilot Study. 61
32320790 2020
42
Inappropriate initial urinary catheter placement among older Chinese hospital inpatients: An observational study. 61
31793146 2020
43
Is baseline routine renal ultrasound indicated for all MS patients? 61
31611266 2020
44
Hiccups triggered by bladder filling after bilateral pontine hemorrhage: A case report. 61
32243359 2020
45
Introducing a novel experimental model of bladder transplantation in mice. 61
32282990 2020
46
The creation and validation of a short form of the Neurogenic Bladder Symptom Score. 61
32196732 2020
47
How early is early? Effect of oxybutynin on bladder dynamics within the first year of life in patients with spina bifida. 61
32115375 2020
48
Effect of electroacupuncture on diabetic neurogenic bladder: A randomized controlled trial protocol. 61
32332636 2020
49
Spectrum of diabetic neuropathies. 61
32206478 2020
50
Utilization of Augmentation Cystoplasty for Myelomeningocele Patients Remained Stable Over the Past Decade. 61
32360629 2020
51
Neurogenic bladder monitoring using the cystomanometer and cystoelastometer. 61
32005418 2020
52
Transureteroureterostomy as an adjunctive antireflux procedure in children undergoing bladder augmentation for neurogenic bladder with major reflux. 61
31932241 2020
53
Interdisciplinary Laparoscopic Implantation of Neuromodulation Leads to the Sacral Plexus for Therapy of Chronic Pelvic Pain and Neurogenic Bladder Dysfunctions. 61
32319187 2020
54
A nonsurgical and nonpharmacological care bundle for preventing upper urinary tract damage in patients with spinal cord injury and neurogenic bladder. 61
31328348 2020
55
Urinary Retention in Spinal Cord Injury. 61
32325138 2020
56
Product evaluation of Hollister's Onli™ ready-to-use hydrophilic intermittent catheter and adherence to a treatment plan using this catheter. 61
32124840 2020
57
Recommendations for evaluation of bladder and bowel function in pre-clinical spinal cord injury research. 61
31556844 2020
58
Impact of long-term epidural electrical stimulation enabled task-specific training on secondary conditions of chronic paraplegia in two humans. 61
32202485 2020
59
Urinary Symptoms and Urodynamic Findings in Patients with Spinocerebellar Ataxia. 61
32193855 2020
60
Outcome of Different Approaches to Reduce Urinary Tract Infection in Patients with Spinal Cord Lesions: A Systematic Review. 61
32149818 2020
61
Urinary Tract Infection in Pediatric Patients on Clean Intermittent Catheterization via a Mitrofanoff port with Reused Catheters - Any Association with Catheter Sterility? 61
32139987 2020
62
Predictors of Urinary Infections and Urosepsis After Ureteroscopy for Stone Disease: a Systematic Review from EAU Section of Urolithiasis (EULIS). 61
32211969 2020
63
Recommendations for evaluation of neurogenic bladder and bowel dysfunction after spinal cord injury and/or disease. 61
32105586 2020
64
Robotic Bladder Neck Reconstruction With Mitrofanoff Appendicovesicostomy in a Neurogenic Bladder Patient. 61
31790786 2020
65
Risk factors for febrile urinary tract infections in the first year after pediatric renal transplantation. 61
31880402 2020
66
Age-related urologic problems in the complex urologic patient. 61
32062806 2020
67
One-Step Reconstruction with a Novel Suspended, Modular, and 3D-Printed Total Sacral Implant Resection of Sacral Giant Cell Tumor with Preservation of Bilateral S1-3 Nerve Roots via a Posterior-Only Approach. 61
31854115 2020
68
Spontaneous vesicorectal fistula: a rare complication of neurogenic bladder. 61
32093659 2020
69
RE: neurogenic bladder is an independent risk factor for complications associated with inflatable penile prosthesis implantation. 61
32071411 2020
70
A risk prediction model of urinary tract infections for patients with neurogenic bladder. 61
32075472 2020
71
Neurogenic bladder: management of the severely impaired patient with complete urethral destruction: ileovesicostomy, suprapubic tube drainage or urinary diversion-is one treatment modality better than another? 61
32055477 2020
72
Need for botulinum toxin injection and bladder augmentation after isolated bladder outlet procedure in pediatric patients with myelomeningocele. 61
31839471 2020
73
Physiology and Pathophysiology of the Autonomic Nervous System. 61
31996619 2020
74
Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. 61
32103708 2020
75
Malpositioned Suprapubic Catheter Results in Perforation of Penile Urethra and Septic Shock. 61
32190512 2020
76
The impact of catheter-based bladder drainage method on urinary tract infection risk in spinal cord injury and neurogenic bladder: A systematic review. 61
31845396 2020
77
Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A. 61
31518199 2020
78
Can bladder shear wave elastography be an alternative method for detection of neurogenic bladder instead of urodynamic study? 61
32318446 2020
79
A randomized, controlled trial of transcutaneous tibial nerve stimulation to treat overactive bladder and neurogenic bladder patients. 61
32017693 2020
80
EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part II operative management. 61
31794087 2020
81
Risk factors for quinolone-resistant Escherichia coli infection: a systematic review and meta-analysis. 61
31938541 2020
82
Can rectal catheters be avoided during paediatric urodynamic studies? 61
32082633 2020
83
The effects of botulinum toxin injection on urodynamic changes in pediatric population with neurospastic bladder: First trial in Iran. 61
32019705 2020
84
EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment. 61
31724222 2020
85
Concurrent urinary and bowel diversion: Surgical modification with sigmoid colon that avoids a bowel anastomosis. 61
31851467 2020
86
Long-term Outcome of Renal Transplantation in Patients with Congenital Lower Urinary Tract Malformations: A Multicenter Study. 61
30964838 2020
87
Efficiency and Safety of the Sting Operation on Kidney Transplanted Patients with Symptomatic Vesicoureteral Reflux and Neurogenic Bladder Dysfunction. 61
31901322 2020
88
Pediatric Neurogenic Bladder and Bowel Dysfunction: Will My Child Ever Be out of Diapers? 61
31982364 2020
89
Laparoscopic selective pudendal neuromodulation for neurogenic bladder: a review of literature. 61
32395321 2020
90
Implantation of Sacral Nerve Stimulator Without Rhizotomy for Neurogenic Bladder in Patient With Spinal Cord Injury: 2-Dimensional Operative Video. 61
31980830 2020
91
Urodynamic Parameters in Spinal Cord Injury-Induced Neurogenic Bladder Rats after Stem Cell Transplantation: A Narrative Review. 61
32038054 2020
92
Engineered Stem Cells Improve Neurogenic Bladder by Overexpressing SDF-1 in a Pelvic Nerve Injury Rat Model. 61
32067480 2020
93
Different types of acupuncture and moxibustion therapy for neurogenic bladder after spinal cord injury: A systematic review and network meta-analysis study protocol. 61
31895798 2020
94
Reasons for cessation of clean intermittent catheterization after spinal cord injury: Results from the Neurogenic Bladder Research Group spinal cord injury registry. 61
31578784 2020
95
The Real Daily Need for Incontinence Aids and Appliances in Patients with Neurogenic Bladder Dysfunction in a Community Setting in Germany. 61
32161466 2020
96
A rare case of emphysematous spongiositis following urethral catheterization: A case report. 61
31641613 2020
97
Transcutaneous Electrical Spinal Cord Neuromodulator (TESCoN) Improves Symptoms of Overactive Bladder. 61
32116576 2020
98
Kidney transplantation using a colon pouch (Mainz pouch III): a case report. 61
31894920 2019
99
The Stockholm Spinal Cord Uro Study: 1. Basic characteristics and problem inventory. 61
31630596 2019
100
[A Case of Neurofibromatosis Type 1 Presenting Voiding Symptoms Caused by Giant Bladder Diverticulum]. 61
31933336 2019
101
Create a predictive model for neurogenic bladder patients: upper urinary tract damage predictive nomogram. 61
31401918 2019
102
Weekly sequential antibioprophylaxis for recurrent UTI among patients with neurogenic bladder: a randomized controlled trial. 61
31867616 2019
103
The use of mirabegron in neurogenic bladder: a systematic review. 61
31802206 2019
104
Evaluation and Long-term Management of Neurogenic Bladder in Spinal Dysraphism. 61
31792158 2019
105
[Acute flaccid paralysis related to enterovirus with complete resolution of the neurological symptoms. A pediatric case report]. 61
31758907 2019
106
Autologous Transplantation of Adipose-Derived Stem Cells to Treat Acute Spinal Cord Injury: Evaluation of Clinical Signs, Mental Signs, and Quality of Life. 61
32215102 2019
107
Clam augmentation enterocystoplasty as management of urge urinary incontinence and reduced bladder capacity. 61
31757178 2019
108
Efficacy and security of continent catheterizable channels at short and middle term for adult neurogenic bladder dysfunction. 61
31540862 2019
109
Transcranial magnetic stimulation and bladder function: A systematic review. 61
31541980 2019
110
Effect of intravesical botulinum toxin injection on symptoms of autonomic dysreflexia in a patient with chronic spinal cord injury: a case report. 61
28486884 2019
111
Utility of Mitrofanoff as bladder draining tool: A single center experience in pediatric patients. 61
30484768 2019
112
Albuminuria in Pediatric Neurogenic Bladder: Identifying an Earlier Marker of Renal Disease. 61
31454657 2019
113
Long-term follow-up of neurogenic bladder patients after bladder augmentation with small intestinal submucosa. 61
31712957 2019
114
Leukoencephalopathy With Predominant Infratentorial Involvement Caused by a Novel ABCD1 Mutation: Does the Spinocerebellar Variant of Adrenoleukodystrophy Exist? 61
31688712 2019
115
Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective. 61
31684987 2019
116
Neurogenic bladder associated with xeroderma pigmentosum type A: A case report and literature review. 61
31467858 2019
117
Immediate effect of transcutaneous electrical nerve stimulation on urodynamic parameters of children with myelomeningocele. 61
31486143 2019
118
[Effect of SU Jia-fu's Wenjing Tongdu external treatment combined with long-snake moxibustion at governor vessel on urodynamic for neurogenic bladder after spinal cord injury]. 61
31724353 2019
119
Unexpected foreign body in the bladder of a spinal cord injured patient: A case report. 61
30557084 2019
120
Transvaginal Cystolithotomy: A Novel Approach. 61
31238047 2019
121
Performance of a Natural Language Processing Method to Extract Stone Composition From the Electronic Health Record. 61
31310771 2019
122
Validation of Upper Extremity Motor Function as a Key Predictor of Bladder Management After Spinal Cord Injury. 61
31348899 2019
123
Reviewing the prognostic factors in myelomeningocele. 61
31574474 2019
124
Modified posterior pelvic exenteration with pelvic side-wall resection requiring both intestinal and urinary reconstruction during surgery for ovarian cancer. 61
31351675 2019
125
Neurogenic bladder in the settings of congenital Zika syndrome: a confirmed and unknown condition for urologists. 61
31142443 2019
126
Urinary tract infections in patients with neurogenic bladder. 61
30885540 2019
127
Recent Updates in Urinary Catheter Products for the Neurogenic Bladder Patients with Spinal Cord Injury. 61
31720260 2019
128
Neurogenic bladder is an independent risk factor for complications associated with inflatable penile prosthesis implantation. 61
31645755 2019
129
Laparoscopic appendicovesicostomy and ileovesicostomy: A step-by-step technique description in neurogenic patients. 61
31649461 2019
130
Pathophysiology of refractory overactive bladder. 61
30900373 2019
131
Outcomes of renal calculi in patients with spinal cord injury. 61
31297852 2019
132
Interferential electrical stimulation for improved bladder management following spinal cord injury. 61
31423306 2019
133
Surgical Management of Anatomic Bladder Outlet Obstruction in Males with Neurogenic Bladder Dysfunction: A Systematic Review. 61
29551557 2019
134
Ureterocystoplasty (bladder augmentation) in a 16 year-old boy with Goldenhar syndrome. 61
31630716 2019
135
A Case of Sulfhemoglobinemia Secondary to a Urinary Tract Infection. 61
31568176 2019
136
Lower urinary tract symptoms treatment constraints assessment (LUTS-TCA): a new tool for a global evaluation of neurogenic bladder treatments. 61
30511213 2019
137
Nursing Care of the Patient With Neurogenic Bladder After Kidney Transplantation: A Case Report. 61
31405733 2019
138
Augmentation cystoplasty in the patient with neurogenic bladder. 61
31511969 2019
139
Feasibility of Self-administered Neuromodulation for Neurogenic Bladder in Spinal Cord Injury. 61
31607105 2019
140
Hydrocephalus associated with multiple Tarlov cysts. 61
31383334 2019
141
Patient Reported Bladder Related Symptoms and Quality of Life after Spinal Cord Injury with Different Bladder Management Strategies. 61
30958741 2019
142
Quality of life after spinal cord